(XYL) Xylem - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98419M1009
Pumps, Meters, Treatment, Analytics, Services
Dividends
| Dividend Yield | 1.15% |
| Yield on Cost 5y | 1.72% |
| Yield CAGR 5y | 8.48% |
| Payout Consistency | 100.0% |
| Payout Ratio | 33.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.7% |
| Value at Risk 5%th | 32.6% |
| Relative Tail Risk | -8.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.39 |
| Alpha | -0.86 |
| CAGR/Max DD | 0.33 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.616 |
| Beta | 0.817 |
| Beta Downside | 0.880 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.73% |
| Mean DD | 8.83% |
| Median DD | 8.55% |
Description: XYL Xylem December 03, 2025
Xylem Inc. (NYSE:XYL) designs, manufactures, and services engineered water-related products for utility, industrial, residential, and commercial markets worldwide. The business is organized into four segments-Water Infrastructure; Applied Water; Measurement & Control Solutions; and Water Solutions & Services-offering a portfolio that spans pumps, treatment equipment, smart meters, data-analytics platforms, and managed maintenance services under brands such as Flygt, Sensus, and Bell & Gossett.
Key recent metrics: FY 2023 revenue reached roughly $5.6 billion, up 7 % YoY, with an adjusted operating margin of ~14 % and free cash flow of $850 million, supporting a 0.5 % dividend yield. The company’s growth is anchored to macro drivers including the U.S. $55 billion water-infrastructure funding bill, rising global water-scarcity concerns, and accelerating ESG capital allocation to resilient water-utility assets. Assuming continued capex rollout and stable demand for digital water-management services, Xylem’s 2024 guidance projects mid-single-digit revenue growth and incremental EPS expansion.
For a deeper quantitative view, you might explore Xylem’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (948.0m TTM) > 0 and > 6% of Revenue (6% = 533.6m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 24.42% (prev 23.28%; Δ 1.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.27b > Net Income 948.0m (YES >=105%, WARN >=100%) |
| Net Debt (898.0m) to EBITDA (1.79b) ratio: 0.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (244.1m) change vs 12m ago 0.14% (target <= -2.0% for YES) |
| Gross Margin 38.23% (prev 36.97%; Δ 1.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.35% (prev 52.50%; Δ 0.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 38.12 (EBITDA TTM 1.79b / Interest Expense TTM 32.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.55
| (A) 0.13 = (Total Current Assets 4.44b - Total Current Liabilities 2.27b) / Total Assets 17.30b |
| (B) 0.20 = Retained Earnings (Balance) 3.47b / Total Assets 17.30b |
| (C) 0.07 = EBIT TTM 1.22b / Avg Total Assets 16.67b |
| (D) 0.55 = Book Value of Equity 3.24b / Total Liabilities 5.85b |
| Total Rating: 2.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.73
| 1. Piotroski 6.50pt |
| 2. FCF Yield 2.65% |
| 3. FCF Margin 10.40% |
| 4. Debt/Equity 0.19 |
| 5. Debt/Ebitda 0.50 |
| 6. ROIC - WACC (= -1.33)% |
| 7. RoE 8.67% |
| 8. Rev. Trend 92.99% |
| 9. EPS Trend 89.47% |
What is the price of XYL shares?
As of December 04, 2025, the stock is trading at USD 139.42 with a total of 1,191,610 shares traded.
Over the past week, the price has changed by -1.48%, over one month by -6.22%, over three months by -0.38% and over the past year by +11.08%.
Over the past week, the price has changed by -1.48%, over one month by -6.22%, over three months by -0.38% and over the past year by +11.08%.
Is XYL a buy, sell or hold?
Xylem has received a consensus analysts rating of 4.05.
Therefore, it is recommended to buy XYL.
- Strong Buy: 9
- Buy: 5
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the XYL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 167.8 | 20.3% |
| Analysts Target Price | 167.8 | 20.3% |
| ValueRay Target Price | 150.1 | 7.6% |
XYL Fundamental Data Overview December 03, 2025
Market Cap USD = 33.94b (33.94b USD * 1.0 USD.USD)
P/E Trailing = 35.9304
P/E Forward = 25.4453
P/S = 3.8163
P/B = 3.056
P/EG = 2.1486
Beta = 1.168
Revenue TTM = 8.89b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.79b USD
Long Term Debt = 1.91b USD (from longTermDebt, last quarter)
Short Term Debt = 176.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 898.0m USD (from netDebt column, last quarter)
Enterprise Value = 34.84b USD (33.94b + Debt 2.09b - CCE 1.19b)
Interest Coverage Ratio = 38.12 (Ebit TTM 1.22b / Interest Expense TTM 32.0m)
FCF Yield = 2.65% (FCF TTM 925.0m / Enterprise Value 34.84b)
FCF Margin = 10.40% (FCF TTM 925.0m / Revenue TTM 8.89b)
Net Margin = 10.66% (Net Income TTM 948.0m / Revenue TTM 8.89b)
Gross Margin = 38.23% ((Revenue TTM 8.89b - Cost of Revenue TTM 5.49b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 38.77%)
Tobins Q-Ratio = 2.01 (Enterprise Value 34.84b / Total Assets 17.30b)
Interest Expense / Debt = 0.29% (Interest Expense 6.00m / Debt 2.09b)
Taxrate = 23.91% (71.0m / 297.0m)
NOPAT = 928.4m (EBIT 1.22b * (1 - 23.91%))
Current Ratio = 1.96 (Total Current Assets 4.44b / Total Current Liabilities 2.27b)
Debt / Equity = 0.19 (Debt 2.09b / totalStockholderEquity, last quarter 11.21b)
Debt / EBITDA = 0.50 (Net Debt 898.0m / EBITDA 1.79b)
Debt / FCF = 0.97 (Net Debt 898.0m / FCF TTM 925.0m)
Total Stockholder Equity = 10.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 948.0m / Total Assets 17.30b)
RoE = 8.67% (Net Income TTM 948.0m / Total Stockholder Equity 10.93b)
RoCE = 9.50% (EBIT 1.22b / Capital Employed (Equity 10.93b + L.T.Debt 1.91b))
RoIC = 7.18% (NOPAT 928.4m / Invested Capital 12.93b)
WACC = 8.51% (E(33.94b)/V(36.03b) * Re(9.02%) + D(2.09b)/V(36.03b) * Rd(0.29%) * (1-Tc(0.24)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.54%
[DCF Debug] Terminal Value 78.33% ; FCFE base≈886.2m ; Y1≈1.09b ; Y5≈1.87b
Fair Price DCF = 108.7 (DCF Value 26.45b / Shares Outstanding 243.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 89.47 | EPS CAGR: 23.02% | SUE: 3.80 | # QB: 4
Revenue Correlation: 92.99 | Revenue CAGR: 15.46% | SUE: 0.87 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=12
EPS next Year (2026-12-31): EPS=5.55 | Chg30d=+0.159 | Revisions Net=+17 | Growth EPS=+9.9% | Growth Revenue=+3.6%
P/E Trailing = 35.9304
P/E Forward = 25.4453
P/S = 3.8163
P/B = 3.056
P/EG = 2.1486
Beta = 1.168
Revenue TTM = 8.89b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.79b USD
Long Term Debt = 1.91b USD (from longTermDebt, last quarter)
Short Term Debt = 176.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 898.0m USD (from netDebt column, last quarter)
Enterprise Value = 34.84b USD (33.94b + Debt 2.09b - CCE 1.19b)
Interest Coverage Ratio = 38.12 (Ebit TTM 1.22b / Interest Expense TTM 32.0m)
FCF Yield = 2.65% (FCF TTM 925.0m / Enterprise Value 34.84b)
FCF Margin = 10.40% (FCF TTM 925.0m / Revenue TTM 8.89b)
Net Margin = 10.66% (Net Income TTM 948.0m / Revenue TTM 8.89b)
Gross Margin = 38.23% ((Revenue TTM 8.89b - Cost of Revenue TTM 5.49b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 38.77%)
Tobins Q-Ratio = 2.01 (Enterprise Value 34.84b / Total Assets 17.30b)
Interest Expense / Debt = 0.29% (Interest Expense 6.00m / Debt 2.09b)
Taxrate = 23.91% (71.0m / 297.0m)
NOPAT = 928.4m (EBIT 1.22b * (1 - 23.91%))
Current Ratio = 1.96 (Total Current Assets 4.44b / Total Current Liabilities 2.27b)
Debt / Equity = 0.19 (Debt 2.09b / totalStockholderEquity, last quarter 11.21b)
Debt / EBITDA = 0.50 (Net Debt 898.0m / EBITDA 1.79b)
Debt / FCF = 0.97 (Net Debt 898.0m / FCF TTM 925.0m)
Total Stockholder Equity = 10.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 948.0m / Total Assets 17.30b)
RoE = 8.67% (Net Income TTM 948.0m / Total Stockholder Equity 10.93b)
RoCE = 9.50% (EBIT 1.22b / Capital Employed (Equity 10.93b + L.T.Debt 1.91b))
RoIC = 7.18% (NOPAT 928.4m / Invested Capital 12.93b)
WACC = 8.51% (E(33.94b)/V(36.03b) * Re(9.02%) + D(2.09b)/V(36.03b) * Rd(0.29%) * (1-Tc(0.24)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.54%
[DCF Debug] Terminal Value 78.33% ; FCFE base≈886.2m ; Y1≈1.09b ; Y5≈1.87b
Fair Price DCF = 108.7 (DCF Value 26.45b / Shares Outstanding 243.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 89.47 | EPS CAGR: 23.02% | SUE: 3.80 | # QB: 4
Revenue Correlation: 92.99 | Revenue CAGR: 15.46% | SUE: 0.87 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=12
EPS next Year (2026-12-31): EPS=5.55 | Chg30d=+0.159 | Revisions Net=+17 | Growth EPS=+9.9% | Growth Revenue=+3.6%
Additional Sources for XYL Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle